首页> 美国卫生研究院文献>American Journal of Blood Research >High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease
【2h】

High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease

机译:高剂量甲氨蝶呤和长时间高通量血液透析治疗晚期肾病患者的原发性中枢神经系统淋巴瘤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This report discusses the case of a 52 year old female with post-transplant lymphoproliferative disorder, confined to the central nervous system, which was managed with high dose methotrexate (HDMTX) in the context of end stage renal disease. The patient received two doses of HDMTX followed by extended hours high-flux hemodialysis, plasma methotrexate concentration monitoring and leucovorin rescue. The hemodialysis technique used was effective in clearing plasma methotrexate and allowed delivery of HDMTX to achieve complete remission with limited and reversible direct methotrexate-related toxicity. Dialysis-dependent renal failure does not preclude the use of HDMTX when required for curative therapy of malignancy.
机译:本报告讨论了一名52岁女性,患有移植后淋巴组织增生性疾病,仅限于中枢神经系统,在终末期肾脏疾病的背景下使用高剂量甲氨蝶呤(HDMTX)进行治疗。患者接受了两剂HDMTX,随后进行了长时间的高通量血液透析,血浆氨甲蝶呤浓度监测和亚叶酸钙拯救。所使用的血液透析技术可有效清除血浆甲氨蝶呤,并允许HDMTX输送,从而实现完全缓解,而甲氨蝶呤相关的毒性有限且可逆。当需要进行恶性肿瘤的根治性治疗时,依赖于透析的肾衰竭并不排除使用HDMTX。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号